SXTP

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 2025. Operating expenses were approximately $2.33 million for the second quarter of 2026, compared with approximately $1.86 million for the second quarter of 2025. Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, for the second quarter of 2026, compared with a net loss of approximately $1.84 million, or $5.01 per share, for the second quarter of 2025. Additional information regarding the Company's results is available in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact:Kristen [email protected] Investor Contact:Patrick [email protected]

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026. The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarter of 2025. Operating expenses were approximately $2.17 million in the first quarter of 2026, compared with approximately $2.09 million in the first quarter of 2025. Net loss attributable to common shareholders in the first quarter of 2026 was approximately $2.21 million, or a net loss of $1.28 per share, compared with a net loss of approximately $2.00 million, or a net loss of $6.25 per share, in the first quarter of 2025. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Australian Chestnut Extract and/or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact:Sheila A. [email protected](484) 667-6330 Investor Contact:Patrick [email protected](310) 989-5666

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns. The Company achieved a gross profit of approximately $223.8 thousand in 2025, compared with approximately $222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs associated with a final batch of short-dated product entering the supply chain. This charge was a necessary, non-recurring cost incurred as part of scaling operations. Operating expenses were approximately $8.4 million in 2025, compared with approximately $10.0 million in 2024. The decrease in Research and Development costs of $2.9 million was due to 2024 including $3.2 million of non-cash and non-recurring charges. The increase in general and administrative expenses of $1.3 million was driven primarily by $967.6 thousand in additional sales advisory, advertising and promotion expenses. Net loss attributable to common shareholders in 2025 was approximately $7.37 million, or $11.73 per share, compared with a net loss of approximately $7.96 million, or $74.17 per share, in 2024 — an improvement of approximately $590 thousand. This improvement was driven primarily by the absence of non-recurring, non-cash Research and Development charges that burdened fiscal year 2024, partially offset by higher selling expenses in fiscal year 2025 and a $1.4 million reduction in the favorable Change in Fair Value of Derivative Liabilities. Recent Business Highlights: As of March 30, 2026, the Company had 2,636,788 shares outstanding. In the 12 months through March 27, 2026 the Company had offered and sold approximately $4,026,722 in common shares using its At-the-Market facility, exhausting current baby shelf capacity. In March 2026, the Company announced that all patients enrolled in its expanded access study for relapsing babesiosis were cured after tafenoquine-based treatment and called for treatment guidelines to be reviewed in light of the new data. The Company believes that the next clinical data release, the interim analysis of its randomized hospital study, could occur as early as late September if recruitment patterns of the 2026 tick season mirror those of the 2025 season. In February 2026, the Company partnered with GoodRx to provide eligible consumers savings of up to 30% on ARAKODA®, expanding sales footprint to more than 70,000 pharmacies nationwide. In January 2026, the Company partnered with Runway Health to expand sales of ARAKODA® for malaria prevention through a travel-focused telehealth platform. In January 2026, the Company exercised its Florida State University license option for large-scale purification of castanospermine and signaled readiness to commence the regulatory process for Australian Chestnut Extract as a non-prescription botanical product. In November 2025, the central study site at Mount Sinai opened for patient enrollment in the Phase 2 B-FREE Chronic Babesiosis Study, which is designed to run about 12 months and enroll up to 100 patients. In July 2025, the Company entered into a sponsored research agreement with Tulane University to evaluate tafenoquine activity against Borrelia (Lyme) and Bartonella bacteria. In April 2025, the Company announced a patent license agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for babesiosis treatment and prevention. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors, including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators, future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen), Australian Chestnut Extract or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected] (310) 989-5666

Q3 2025 net product revenue increased 223% year-over-year to $438 thousand Gross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025: ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025). The Company posted a gross loss of approximately $100 thousand in the third quarter of 2025, compared to an approximate gross profit of $24 thousand in the third quarter of 2024, due to a one-time inventory write-off associated with newly produced validation lots which will no longer be accepted by supply chain partners after the end of Q1 2026 due to limited remaining shelf-life. Additional lots with four-year shelf-life are currently in production and expected to fully enter the supply chain in early Q1 2026. Operating expenses were approximately $2.32 million in the third quarter of 2025, compared to approximately $2.16 million in the third quarter of 2024. The increase in expenses is primarily driven by the $367 thousand in additional advertising and sales promotion expenditures. Net loss attributable to common shareholders in the third quarter of 2025 was approximately $2.44 million, or ($0.66) per share, compared to approximately $2.27 million, or ($4.65) per share in the third quarter of 2024, representing an additional $171K in losses. Business Highlights for the Quarter Ended September 30, 2025: On July 14, 2025, we announced our intention to seek a Minor Use Minor Species (MUMS) designation from the United States Food and Drug Administration (FDA) for the treatment of acute canine babesiosis following a comprehensive gap analysis of our existing data. After completing a 6,000 patient nationwide survey and quantitative research study, we announced on July 15, 2025 that we had determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035. On July 17, 2025, we announced our entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against Borrelia (Lyme) and Bartonella bacteria. On August 19, 2025, we announced our partnership with the Icahn School of Medicine at Mount Sinai for our planned Phase II clinical study of tafenoquine in treating chronic babesiosis. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of vector-borne disease. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based Pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir/Australian Chestnut Extracts in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected]

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025. While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary disruption of supply of ARAKODA® 16-count boxes. Provided the Company reaches minimum enrollment in its hospitalized babesiosis study prior to the end of the 2025 tick season in early October, the Company’s current cash position is expected to allow the trial’s interim analysis to be conducted prior to the need for additional capital. Financial Highlights: Q2 2025 net product revenues decreased 19% year-over-year from $125 thousand to $101 thousand. This was associated with a decrease of 17% in ARAKODA pharmacy deliveries, from 1,301 boxes (Q2 2024) to 1,082 16-count box equivalents (Q2 2025). This occurred due to a temporary disruption of supply of ARAKODA 16-count boxes which was incompletely mitigated by the introduction of the new 8-count ARAKODA bottle, and importation, with FDA consent, of KODATEF (tafenoquine 16-count boxes). New commercial lots of ARAKODA 16-count boxes are anticipated to enter the supply chain in September, 2025. The Company achieved a gross profit of approximately $51 thousand in the second quarter of 2025, compared to an approximate gross profit of $35 thousand in the second quarter of 2024. This was primarily due to lower overall cost of sales and via the sale of KODATEF 16-count boxes (which had fewer discounts/rebates). Operating expenses were approximately $1.86 million in the second quarter of 2025, compared to approximately $4.22 million in the second quarter of 2024. This was primarily due to the absence of one-off, non-cash, research and development costs that occurred during the same period in 2024. Net loss attributable to common shareholders in the second quarter of 2025 was approximately $1.84 million, or ($1.25) per share, compared to a net loss of approximately $4.29 million, or ($21.12) per share in the second quarter of 2024, representing a $2.45 million decrease in loss. Based on current internal sales projections and considering the $1.97 million in cash/cash equivalents on hand at June 30, 2025, and the net proceeds of approximately $4.46 million received from our recent July 15 public offering, we expect to remain financially viable through March 31, 2026, assuming no additional capital is raised. If we are successful in enrolling a total of at least 24 patients in our hospitalized babesiosis patient study before the end of the tick season in early October 2025, we expect the trial’s interim data analysis to be conducted prior to March 31, 2026. Business Highlights for the Quarter Ended June 30, 2025 The Company concluded several commercial research studies that collectively suggest that annual incidence of babesiosis is between 25,000 and 380,000 cases and that the total addressable U.S. market for ARAKODA for human babesiosis may approach $1.1 billion over the remaining 10-year patent life. A new 8-count bottle format of ARAKODA was introduced into the U.S. supply chain. This option will reduce the cost of ARAKODA for short-term travelers to malaria-endemic regions of the world. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected] (310) 989-5666

60 Degrees Pharmaceuticals (SXTP) announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health. Results showed approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs each year, according to 60 Degrees Pharmaceuticals. In contrast, current estimates published by the Centers for Disease Control and Prevention show only 2,000 cases in 2020. Babesia infections last at least 12 months in 14 percent of patients and may relapse up to 27 months later, as documented in the scientific literature. Many physicians treating tick-borne infections speculate the true duration of infection may be much longer. The claims data indicated approximately 31 percent of babesiosis cases persist longer than 30 days, and that nearly half of those are associated with chronic fatigue lasting longer than six months. Fatigue is the last symptom of babesiosis to resolve in acute disease. Chronic fatigue during babesiosis has not been systematically described in the literature. Further, the claims data, which captured approximately 40 percent of U.S. diagnostic data, showed that over three years, more than 12 million U.S. adults experienced chronic fatigue greater than six months in duration. Current Infectious Diseases Society of America advice and other professional guidelines do not mandate babesiosis as a differential diagnosis if a patient self-reports experiencing such fatigue. The Company is testing, through its clinical development program, the medical hypothesis that the true burden of babesiosis is much larger than claims data suggest and is a function of the incidence of chronic fatigue lasting six months or longer, multiplied by the proportion of such individuals with confirmable infections. A molecular incidence study in patients with chronic fatigue commissioned by the Company was recently completed. Once published, the data will allow establishment of a ceiling on the incidence of persistent babesiosis. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SXTP: Disclaimer & DisclosureReport an Issue 60 Degrees announces findings from online survey about babesiosis disease 60 Degrees Pharmaceuticals signs Patient License Agreement with Yale

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domestic sales of ARAKODA®. The Company achieved a gross profit of approximately $90.3 thousand in the first quarter of 2025, compared with an approximate gross profit of $40.2 thousand in the first quarter of 2024. Operating expenses were approximately $2.09 million in the first quarter of 2025, compared with approximately $1.41 million in the first quarter of 2024. Increased expenditures in sales and investor-related services along with stock-based compensation accounted for $535.4 thousand of the increase. Net loss attributable to common shareholders in the first quarter of 2025 was approximately $2.01 million, or ($1.56) per share, compared with a net income of approximately $308.7 thousand, or $1.83 per share in the first quarter of 2024. The change in fair value of derivative liabilities accounted for $1.74 million of this difference in income attributable. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected] (310) 989-5666

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people in that category. At the time they replied to the survey, 3.7 percent of respondents – equivalent to about 9.9 million people – reported they had been experiencing fatigue, a common symptom of babesiosis, for six months or longer. WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers for Disease Control and Prevention (CDC) statistics suggest. Preliminary results of an online survey conducted by the Company showed that nearly 3 million Americans (1.26 percent of the adult population in 2020) may have received a babesiosis diagnosis from a medical practitioner in their lifetime. In contrast, CDC reports 1,834 cases of babesiosis in 2020. Even though this annual number relies on different methodologies and timeframes, and is not directly comparable to the Company’s estimates, the disparity suggests the possibility that babesiosis is significantly underdiagnosed or underreported in existing public health reporting data. The Company believes this may indicate a greater demand for effective treatment than suggested by current CDC statistics. The survey included responses from 6,000 participants selected to match the U.S. adult demographic distribution. Babesiosis is a serious, emerging tick-borne disease often found as a co-infection with Lyme disease. It may be life-threatening in immunocompromised and elderly individuals. An as yet untested medical hypothesis advanced by some prescribing physicians in the Lyme disease community is that persistent Babesia infection contributes to chronic fatigue and other problems. If this is true, millions of Americans with persistent fatigue, a common symptom of babesiosis, may be living with an undiagnosed but potentially treatable illness. The Company commissioned the survey as part of its goal to define the size of the commercial market for babesiosis treatment candidates now in development. It was conducted by Format Analytics, an independent market research agency. The online quantitative survey was conducted among a general adult population sample of 6,000 adults, with demographic variables (gender, age, ethnicity, income) matched to U.S. census data for optimal representation of the U.S. population. Babesiosis was reported as a diagnosed medical condition experienced by 1.26 percent of respondents, implying that 3 million Americans may have experienced babesiosis (1.26 percent of 268 million U.S. residents). Moreover, approximately 17 percent of babesiosis patients reported having experienced a duration of illness of six months or more, implying that at least 570,000 U.S. adults have experienced chronic disease (17 percent of 1.26 percent of 268 million U.S. adults). Another objective of the survey was to estimate what proportion of U.S. residents are currently experiencing fatigue lasting longer than six months (inclusive of those who have received a formal diagnosis of chronic fatigue syndrome/encephalomyelitis). Approximately 3.7 percent of respondents to the survey, equivalent to about 9.9 million Americans per a U.S. adult population of 268 million U.S. adults, reported experiencing chronic fatigue of six months or longer at the time the survey was conducted. Approximately 56 percent of them (representing about 1.9 percent of total respondents) reported having received a formal diagnosis of Chronic Fatigue Syndrome (CFS). In contrast, in a 2021/2022 telephone survey, the CDC found that approximately 1.3 percent of respondents had received a formal diagnosis of CFS. “These survey results, which will be submitted for publication soon, suggest that official statistics may not capture the lived experiences of babesiosis patients in the U.S.,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow. “Infectious disease specialists seeking to treat patients who present with unexplained chronic fatigue should consider babesiosis as a differential diagnosis.” About Babesiosis and ARAKODA® Babesiosis is a rapidly emerging tick-borne disease often found as a co-infection with Lyme disease. Based on Lyme disease insurance claims and Babesia co-infection rates, 60 Degrees surmises that approximately 46,000 Americans are diagnosed with acute (short-term) babesiosis each year. Most people recover within 90 days when treated with standard antimicrobials recommended by the Infectious Diseases Society of America. These treatments are assumed to reduce the number of parasites enough for the immune system to clear the rest. However, in some individuals, Babesia infection may persist for at least a year, or they might recover and then feel unwell again up to two years later. Fatigue is usually the last clinical symptom of babesiosis to resolve. The actual number of people living with chronic or persistent (long-term) Babesia infection in the U.S. has not been described in the scientific literature. Medical literature suggests that ARAKODA (tafenoquine), a medicine licensed and manufactured by 60 Degrees may have the potential to clear Babesia parasites and ease symptoms. The Company is currently running two clinical trials (NCT06207370 and NCT06478641) to confirm these findings. A third study is being planned for people with a presumptive diagnosis of babesiosis and experiencing severe and disabling chronic fatigue (NCT06656351). One of the hypotheses the study will test is that 20 percent of patients entering the study will have a Babesia infection confirmable using commercially available molecular tests. ARAKODA is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. ARAKODA has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration (FDA) for such an indication. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma

FY 2024 net product revenues increased 140% to $607.6 thousand. FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the 2024 fiscal year, ended December 31, 2024. Financial Highlights for the Fiscal Year Ended December 31, 2024: Net product revenues increased 140% from $253.6 thousand for fiscal year 2023 to $607.6 thousand for fiscal year 2024; the Company credits growth from domestic commercial sales of ARAKODA®. The Company achieved a gross profit of approximately $222.8 thousand in fiscal year 2024, compared to an approximate gross loss of $221 thousand in fiscal year 2023. Increased sales volume allowed the Company to overcome fixed cost of goods expense associated with the Drug Supply Chain Security Act that previously led to a gross loss. Operating expenses were approximately $10.0 million in fiscal year 2024, compared with approximately $4.9 million in fiscal year 2023. The increase in operating expenses was primarily due to a non-recurring non-cash Research and Development charge of $2.63 million, non-recurring non-cash delivery of research materials ($0.6 million) and Research and Development costs associated with the Company’s babesiosis clinical trial program ($1.36 million). Net loss attributable to common shareholders in calendar year 2024 was approximately $8.43 million, or $18.55 per share, compared with a net loss of approximately $3.925 million, or $59.18 per share in fiscal year 2023, representing a $4.505 million decline. This decline in profitability is mostly attributed to an increase in non-recurring non-cash Research and Development expenses of $3.23 million. Recent Business Highlights Due to a recent surge in demand for Arakoda® in the U.S. market, the Company submitted a regulatory discretion request to FDA in December 2024 to allow importation of Kodatef® (Australian-branded equivalent of Arakoda) to ensure continuous U.S. commercial supply. This was granted in February 2025, and Kodatef was made available for distribution on March 10, 2025, through a specialty pharmacy serving all 50 states. The Company is completing validation of two additional lots of Arakoda, to be released into the supply chain by early Q2 2025. Preparations for the Company’s commercial pilot are complete. Outreach to physicians commenced on March 17, 2025. The Company commenced a randomized evaluation of tafenoquine versus placebo in hospitalized patients with babesiosis in 2024, randomizing N=6 of the minimum 24 patients required to trigger an interim endpoint (all completed the study). The Company recently increased its recruitment capacity for this study by establishing an additional clinical site at Brigham and Women’s Hospital. Interim analysis is expected in Q1 2026. We initiated an open label evaluation of Arakoda in immunosuppressed patients who have a diagnosis of relapsing/persistent babesiosis. The first patient was enrolled during Q1, 2025. Up to 15 patients in total will be enrolled. The epidemiological study sponsored by the Company, and conducted by North Carolina State University, is complete. The study evaluated the incidence of babesiosis by PCR and DNA sequencing in patients with persistent fatigue and neurological problems. Results of the study will be submitted to a peer-reviewed journal. The total prevalence of post-infectious syndromes (severe chronic fatigue, chronic fatigue syndrome, encephalomyelitis, long COVID, and post-treatment Lyme disease syndrome), and the potential contribution of Babesia infection to that burden of disease, is not known. The Company is conducting additional market research to determine the size of these market segments in the U.S., with a view to defining an upper limit on the potential prevalence of chronic babesiosis. The Company has secured IRB (ethics) approval for an open label evaluation of Arakoda in patients with severe fatigue and a presumptive diagnosis of babesiosis. The Company is now establishing the feasibility and cost of conducting such a study. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected] (310) 989-5666